Why people should be concerned about declining Ubiquinol levels | Kanaka Nutrients
Why people should be concerned about declining Ubiquinol levels
and Dr. Robert Barry
Dr. Robert J. Barry who works in Scientific Affairs, Research and New Product Development for Kaneka Nutrients joins eHealth Radio.
Listen to interview with host Eric Michaels & guest Dr. Robert J. Barry discuss the following:
What is Ubiquinol and what are the associated health benefits?
Why should I take a Ubiquinol supplement over a CoQ10 supplement?
If CoQ10 has been available in supplement form for 30 years, why is Ubiquinol only recently available?
Why should people concerned about declining Ubiquinol levels?
What health benefits do Ubiquinol users experience versus CoQ10 users?
How does Ubiquinol work?
Robert J. Barry, Ph.D., works in Scientific Affairs, Research and New Product Development for Kaneka Nutrients, L.P.’s U.S. division. Dr. Barry focuses on clinical research development and collaboration, and on the development of the technical, business and commercial translation of products and technology for Kaneka Nutrients.
Dr. Barry brings more than 15 years of experience in strategic technical development and commercial translation of scientific products, analytical services, drug development and pre-clinical evaluation systems to his position. Prior to joining Kaneka, he co-founded and served as president of a Massachusetts-based drug development company. Under Dr. Barry’s direction, the company identified nine new lead-drug candidates focusing on unmet clinical needs in five disease areas.
Dr. Barry was also a principle advisor for the National Institutes of Health, specializing in the commercial development of biotech start-up companies, their technologies and products. He also founded and served as president of a premier independent testing laboratory and scientific research company serving the natural products industry. Prior to that, Dr. Barry developed a natural products division for a major analytical device company where he served as vice president and chief technical officer.
Dr. Barry earned his bachelor’s degree in biology from Boston College and his Ph.D. in chemistry/biochemistry from the University of Maryland; conducted postdoctoral research in biological chemistry and molecular pharmacology at Harvard Medical School; and was a staff researcher in neuropathology at Harvard Medical School.
He is an active member of numerous professional associations including the American Chemical Society and the American Association for the Advancement of Science.